Should I get a pathology second opinion for cancer

May 19, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Should You Get a Pathology Second Opinion?

This is an excellent question, and the short answer is: yes, getting a second opinion on your pathology is often a smart decision, especially for cancer diagnosis. Here's what you should know:

Why Pathology Second Opinions Matter

Pathology is the foundation of your entire treatment plan. Your pathology report determines:

  • Your cancer type and subtype
  • Grade (how aggressive it is)
  • Biomarkers (like ER/PR, HER2, PD-L1, BRCA status)
  • Stage
  • Which treatments are appropriate for you

If the pathology interpretation is incorrect, everything downstream—your treatment recommendations, prognosis discussions, and clinical trial eligibility—could be affected.

When Second Opinions Are Particularly Important

According to NCCN Guidelines, second opinions are especially valuable when:

  • You have a rare cancer type or subtype
  • Your diagnosis is complex or unusual
  • Biomarker results will significantly impact treatment decisions
  • You're considering a major treatment decision (surgery, chemotherapy, radiation)
  • Your initial pathology report is unclear or incomplete
  • You want confirmation before starting treatment

How to Get a Pathology Second Opinion

  1. Request your slides and blocks: Ask your original pathologist or hospital to send your tissue samples (paraffin blocks) and glass slides to another pathologist
  2. Choose an experienced reviewer: Consider a pathologist at a major cancer center or academic medical center
  3. Provide context: Share your clinical information so the reviewing pathologist understands the full picture
  4. Timeline: This typically takes 1-2 weeks and shouldn't significantly delay treatment

What to Expect

  • The second pathologist will review your slides independently
  • They may agree completely, suggest minor clarifications, or identify important differences
  • Most often (in the majority of cases), second opinions confirm the original diagnosis
  • Sometimes they add important details about biomarkers or grade
  • Occasionally, they identify a different diagnosis—which is exactly why the review is valuable

Cost Considerations

  • Many major cancer centers offer this service
  • Some insurance plans cover second opinion pathology reviews
  • Cost typically ranges from $300-$1,000 if not covered
  • Many patients consider this a worthwhile investment given the stakes

Questions to Ask Your Oncologist

  1. "Do you recommend a pathology second opinion in my case?"
  2. "Which pathologist or institution would you suggest for a second opinion?"
  3. "Will getting a second opinion delay my treatment start date?"
  4. "Are there specific aspects of my pathology report you'd like confirmed?"

Bottom Line

According to the American Cancer Society, seeking a second opinion—whether on pathology, imaging, or treatment recommendations—is a standard and encouraged practice in cancer care. It's not an insult to your original pathologist; it's good medical practice and helps ensure you have the most accurate diagnosis possible before making major treatment decisions.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2

It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated

Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter